FEATURED AUTHORITIES ON RHEUMATOID ARTHRITIS
iQ&A interactive Medical Intelligence Zone welcomes your questions and your participation in the iQ&A community.
How do we motivate physicians and patients to deploy biosimilars as their go-to therapies?
In general, can we extrapolate efficacy of biosimilars across all the disease states for which the originator has indication?
What does the landscape for biosimilars look like for RA and other connective tissue disorders look like?
Can you discuss the immunogencity issues —i.e., anti-drug antibodies (ADAs) — for biosimilars vs reference biologics; and how we can apply results of clinical trials comparing biosimilar anti-TNFs to the front lines of drug selection and RA patient care?
How will we make drug selection and sequencing choices now that biosimilars, including ant-TNF agents, are available?
What factors fueled the introduction of biosimilars?
How should clinicians managing patients with RA select among available agents, including biosimilars for infliximab?
What is the real world data supporting the use of infliximab biosimilars such as INFLIXIMAB-DYYB?
The naming of the biosimilars is creating a lot of confusion. Can you give us a roadmap for making sense of the naming strategies for these drugs?
How “similar” are biosimilars to the originator product? What confidence intervals are acceptable and what level of analytical rigor and drift are acceptable? What parameters must be synchronized between the originator and biosimilar to ...
How do we educate clinicians and pharmacists to ensure and facilitate appropriate, safe, outcome- and cost-effective deployment of anti-TNF biosimilars in the setting of RA, AS, and related conditions?
Can you explain current policy guidance as it relates to biosimilars, including considerations that do or do not apply to “extrapolation,” “substitutability,” and/or “interchangeability” for anti-TNF biosimilars? And what are the product naming guidelines?